title: Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
abstract: Various therapies have been tried for psoriasis. In Japan, biologics began to be used for psoriasis treatment in January 2010. Their clinical efficacy is well known, but biologics cannot be used in all psoriasis patients for reasons such as side-effects and cost. It is necessary to evaluate the effect of long-term psoriasis treatment, but there have been no reports evaluating long-term treatment. Therefore, the outcomes of patients who had been treated at the Tokai University Hospital for more than 5 years, before biological agents were released, were examined. Three categories, classified by initial severity, changes in severity by method of treatment and background characteristics, were investigated. In conclusion, cases of long-term treatment with a combination of topical corticosteroid and topical vitamin D3 analog or oral cyclosporin were found to be effective therapies. Patients with a history of diabetes mellitus or cardiovascular disease of psoriasis were likely to be treatment resistant.
authors: Department of Dermatology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
authors: Emiko
authors: E
authors: Akasaka
authors: Tomotaka
authors: T
authors: Mabuchi
authors: Yasuaki
authors: Y
authors: Manabe
authors: Eiichiro
authors: E
authors: Yahagi
authors: Azusa
authors: A
authors: Yamada-Hiruma
authors: Hanako
authors: H
authors: Yamaoka
authors: Tomoko
authors: T
authors: Kojima
authors: Masayuki
authors: M
authors: Kato
authors: Norihiro
authors: N
authors: Ikoma
authors: Akira
authors: A
authors: Ozawa
authors: Yasuo
authors: Y
authors: Haruki
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002762:Cholecalciferol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005050:Etretinate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010789:Phototherapy / Q000379:methods*; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D002762:Cholecalciferol; D005050:Etretinate; D016572:Cyclosporine